Xenon pharmaceuticals inc. (XENE)
Balance Sheet / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Dec'13
Assets
Current assets:
Cash and cash equivalents

24,755

37,671

37,075

52,180

67,754

87,962

47,435

17,200

20,486

14,688

23,090

20,160

17,095

54,135

35,210

56,064

58,651

65,469

64,346

65,917

72,026

37,950

Marketable securities

116,603

56,932

64,726

58,249

51,552

39,166

15,835

17,878

23,181

29,084

28,606

37,867

47,051

15,356

15,528

-

-

-

9,354

9,464

12,015

11,326

Accounts receivable

813

209

171

132

151

180

171

432

438

129

198

189

200

595

658

386

315

274

188

1,205

215

440

Prepaid expenses and other current assets

2,695

1,666

1,353

1,486

1,875

2,185

909

1,151

716

1,086

739

925

1,329

1,264

1,996

1,818

1,900

371

465

464

686

153

Total current assets

144,866

96,478

103,325

112,047

121,332

129,493

64,350

36,661

44,821

44,987

52,633

59,141

65,675

71,350

53,392

58,268

60,866

66,114

74,353

77,050

84,942

49,869

Operating lease right-of-use asset (note 8)

933

1,036

1,135

1,233

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses, long-term

-

-

-

-

-

-

-

-

230

218

285

269

408

479

632

1,094

1,094

1,700

-

-

-

-

Deferred financing fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,739

Property, plant and equipment, net (note 7)

1,660

1,212

1,316

1,198

991

962

1,086

1,101

1,070

1,154

1,308

1,376

1,404

1,542

1,663

1,790

1,989

2,130

2,174

2,353

2,476

1,879

Deferred tax assets (note 15)

238

178

116

72

105

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total assets

147,697

98,904

105,892

114,550

122,428

130,455

65,436

37,762

46,121

46,359

54,226

60,786

67,487

73,371

55,687

61,152

63,949

69,944

76,527

79,403

87,418

54,487

Liabilities and shareholders’ equity
Current liabilities:
Accounts payable and accrued expenses (note 9)

8,818

7,923

6,676

5,794

4,119

4,413

3,094

2,388

3,383

3,058

3,774

3,591

3,586

3,976

2,929

2,872

2,625

2,823

2,278

1,530

2,664

2,283

Deferred revenue (note 13)

29,743

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability (note 8)

168

158

587

582

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Term loan (note 10)

4,650

3,616

2,067

-

-

-

-

1,400

700

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

157

2,513

5,635

8,724

11,622

15,920

Fair value of liability classified stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,103

6,298

-

-

Total current liabilities

43,379

11,697

9,330

6,376

4,119

4,413

3,094

3,788

4,083

-

-

-

3,586

3,976

2,929

2,872

2,782

5,336

12,016

16,552

14,286

18,203

Deferred revenue, long-term (note 13)

709

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability, long-term (note 8)

743

857

573

722

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Term loan, long-term (note 10)

10,889

11,786

13,202

15,139

15,014

14,886

11,721

5,476

6,104

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, less current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

157

11,886

Deferred tenant inducements

-

-

-

-

-

-

-

-

-

-

-

-

-

86

101

117

133

149

-

-

196

-

Deferred tenant inducements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

164

180

-

282

Total liabilities

55,720

24,340

23,105

22,237

19,133

19,299

14,815

9,264

10,187

3,058

3,774

3,591

3,586

4,062

3,030

2,989

2,915

5,485

12,180

16,732

14,639

30,371

Shareholders’ equity:
Preferred shares, without par value; unlimited shares authorized; issued and outstanding: 1,016,000 (December 31, 2018 - 1,016,000) (note 11)

7,732

7,732

7,732

7,732

7,732

11,932

21,825

21,825

-

-

-

-

-

-

-

-

-

-

-

-

-

102,488

Common shares, without par value; unlimited shares authorized; issued and outstanding: 28,139,228 (December 31, 2018 - 25,750,721) (note 11)

294,244

266,425

266,062

266,040

265,923

261,655

177,012

147,887

173,841

173,841

173,841

173,829

173,246

172,886

148,867

148,728

148,634

148,359

147,824

147,508

147,157

6,147

Additional paid-in capital

40,646

39,676

39,391

38,932

38,515

37,886

37,718

36,919

36,471

35,773

35,182

34,557

34,326

34,117

33,752

33,381

33,083

32,844

29,314

29,083

30,346

-

Additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

29,722

Accumulated deficit

-249,655

-238,279

-229,408

-219,401

-207,885

-199,327

-184,944

-177,143

-173,388

-165,323

-157,581

-150,201

-142,681

-136,704

-128,972

-122,956

-119,693

-115,754

-111,801

-112,930

-103,734

-116,752

Accumulated other comprehensive loss

-990

-990

-990

-990

-990

-990

-990

-990

-990

-990

-990

-990

-990

-990

-990

-990

-990

-990

-990

-990

-990

2,511

Shareholders' equity

91,977

74,564

82,787

92,313

103,295

111,156

50,621

28,498

35,934

43,301

50,452

57,195

63,901

69,309

52,657

58,163

61,034

64,459

64,347

62,671

72,779

-78,372

Total liabilities and shareholders’ equity

147,697

98,904

105,892

114,550

122,428

130,455

65,436

37,762

46,121

46,359

54,226

60,786

67,487

73,371

55,687

61,152

63,949

69,944

76,527

79,403

87,418

54,487

Commitments and contingencies (note 14)

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

-